Leap Therapeutics reports updated results from Phase B of DeFianCe study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy ?
Study Results: Leap Therapeutics reported updated results from the DeFianCe study, showing significant improvements in progression-free survival (PFS) for patients with advanced microsatellite stable colorectal cancer treated with sirexatamab, DKN-01, in combination with bevacizumab and chemotherapy.
Patient Subgroups: The data highlighted particularly strong benefits for patients with high levels of DKK1, those who were VEGF-naive, and individuals with liver metastasis, indicating a positive trend in overall response rate (ORR) and PFS across the second-line CRC population.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
